Treatment
Homoharringtonine clinical trials
We’re tracking 13 recruiting studies that include Homoharringtonine, each written for real people, not researchers, below.
Recruiting studies
- NCT06834321RecruitingPhase 2
Homoharringtonine with hormone therapy before prostate surgery
This trial tests a new combination of a chemotherapy drug (homoharringtonine) and hormone therapy (androgen deprivation) given before surgery to shrink prostate cancer that has spread a little or is advanced. The goal is to see if this approach can help control the cancer better before the prostate is removed.
Nanjing, JiangsuAges 18–85 - NCT05805098RecruitingPhase 2/Phase 3
Testing Venetoclax with chemo for newly diagnosed AML
This trial studies whether adding venetoclax to standard induction chemotherapy (homoharringtonine plus cytarabine) can improve outcomes for people with newly diagnosed AML. It mainly looks at people who can safely receive intensive chemotherapy but have certain heart, kidney, or lung limits.
Suzhou, JiangsuAges 18–60 - NCT06483906RecruitingPhase 2
Study of a drug combo and stem cell transplant for high-risk AML
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
Shanghai, Shanghai MunicipalityAges 18–55 - NCT07163910RecruitingPhase 2
Homoharringtonine plus hormone therapy before prostate surgery
This trial tests whether adding a drug called homoharringtonine (a type of chemotherapy) to standard hormone therapy before prostate surgery can improve outcomes for men with certain stages of prostate cancer. It's for men who haven't had any previous treatment and plan to have their prostate removed.
Nanjing, JiangsuAges 18–85 - NCT07131059Recruiting
Study for MRD-positive AML in remission
This trial is for people with acute myeloid leukemia (AML) who are in remission but still have tiny traces of leukemia cells that can be found with sensitive tests (called MRD-positive). The study is testing a new treatment approach to try to get rid of those remaining cells and prevent the cancer from coming back.
Tianjin, Tianjin MunicipalityAges 14 years+ - NCT06265545Recruiting
Study for relapsed or hard-to-treat AML
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
TianjinAges Any age - NCT06361329RecruitingPhase 3
Comparing new drug combo to standard chemo for ETP-ALL
This trial compares a new combination of drugs (venetoclax plus chemotherapy) to standard chemotherapy for people newly diagnosed with a rare type of T-cell leukemia called ETP-ALL. The goal is to see if the new regimen works better.
Hangzhou, ZhejiangAges 14–75 - NCT05726110RecruitingPhase 3
Selinexor for relapsed or refractory AML in combination treatments
This Phase 3 trial studies selinexor (a medicine that changes signals inside cancer cells) used together with other leukemia treatment regimens for adults whose acute myeloid leukemia (AML) has come back or did not respond to standard therapy. It may help people reach remission or control the disease better than the current approach.
Taiyuan, ShanxiAges 18–60 - NCT06221683RecruitingPhase 2
Personalized induction therapy for children with AML based on genetics
This trial tests different induction therapy options based on the specific genetic subtype of a child’s AML and how the leukemia responds early on. The goal is to personalize treatment to improve outcomes and reduce side effects.
Hefei, AnhuiAges Up to 18 years - NCT06742463RecruitingPhase 2
VHAG for relapsed or refractory T-cell acute leukemia
This trial tests a combination of drugs (venetoclax, homoharringtonine, cytarabine, and g-CSF, called VHAG) for people whose T-cell acute leukemia or lymphoma has come back or hasn't responded to treatment. It aims to see if this combination can help when other treatments haven't worked.
Hangzhou, ZhejiangAges 14–74 - NCT06855810RecruitingPhase 2/Phase 3
New treatment study for children with T-cell ALL
This study tests a new treatment plan for children and teens newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL). It aims to see if the approach is safe and works well, and might offer a more tailored therapy for this specific type of leukemia.
Hefei, AnhuiAges 1 month–18 years - NCT07651176Enrolling by invitationPhase 2/Phase 3
Comparing three chemotherapy approaches for newly diagnosed AML
This study tests three different chemotherapy regimens (LDA, LHAA, and DA) in adults aged 18–65 with newly diagnosed acute myeloid leukemia (AML, a blood cancer). The goal is to find which approach works best and is safest for patients fit enough for intensive treatment.
Hangzhou, ZhejiangAges 18–65 - NCT07651163Enrolling by invitationPhase 2/Phase 3
Comparing three chemotherapy regimens for newly diagnosed blood cancer
This trial tests three different chemotherapy regimens for adults 15–65 years old with newly diagnosed acute myeloid leukemia (AML)—a serious blood cancer. The goal is to see which treatment approach works best for patients with intermediate or high-risk disease who are fit enough for intensive chemotherapy.
Hangzhou, ZhejiangAges 15–65
What Homoharringtonine is being studied for
Conditions with recruiting Homoharringtonine studies.
Common questions
- Are there clinical trials studying Homoharringtonine?
- Yes. Clin2 currently lists 13 recruiting studies that include Homoharringtonine, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Homoharringtonine trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Homoharringtonine an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Homoharringtonine or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.